DDInter195 DDInter1658
Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and negligible mineralocorticoid activity.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Betamethasone {u} (Compound) resembles {v} (Compound) Mometasone
Betamethasone {u} (Compound) resembles {v} (Compound) Fludrocortisone
Betamethasone {u} (Compound) treats {v} (Disease) allergic rhinitis
Betamethasone {u} (Compound) binds {v} (Gene) CYP3A4
Betamethasone {u} (Compound) upregulates {v} (Gene) GSPT1
Betamethasone {u} (Compound) palliates {v} (Disease) kidney cancer
Betamethasone {u} (Compound) is included by {v} (Pharmacologic Class) Corticosteroid Hormone Receptor Agonists
Betamethasone {u} (Compound) downregulates {v} (Gene) DDIT3
Betamethasone {u} (Compound) causes {v} (Side Effect) Blindness
Betamethasone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Orciprenaline
Betamethasone (Compound) resembles Mometasone (Compound)
Betamethasone (Compound) resembles Fludrocortisone (Compound)
Betamethasone (Compound) treats allergic rhinitis (Disease)
Betamethasone (Compound) binds CYP3A4 (Gene)
Betamethasone (Compound) upregulates GSPT1 (Gene)
Betamethasone (Compound) palliates kidney cancer (Disease)
Betamethasone (Compound) is included by Corticosteroid Hormone Receptor Agonists (Pharmacologic Class)
Betamethasone (Compound) downregulates DDIT3 (Gene)
Betamethasone (Compound) causes Blindness (Side Effect)
Betamethasone may cause a minor interaction that can limit clinical effects when taken with Orciprenaline